Michael Berendt
Chairman at Anchor Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Albert Bourla | M | 62 | 31 years | |
| Flemming Ørnskov | M | 66 | 7 years | |
| Joe D. Carrabino | M | 62 |
AEA Investors LP
 AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Douglas Lankler | M | 58 | 25 years | |
| Keeley Aleman | F | - | 18 years | |
| Udit Batra | M | 53 | 4 years | |
| Tom W. S. Groves | M | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Michael Silveira | M | 58 | 20 years | |
| Wei Jiang | M | 60 | 3 years | |
| Pearl Shirley Huang | M | 66 | 3 years | |
| Rady Johnson | M | 63 | 30 years | |
| Vinay Kumar | M | 46 |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Linda Baddour | F | 65 | 6 years | |
| James Ho | M | 45 |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 23 years |
| Scott E. Zoellner | M | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Christopher Kuebler | M | 70 | 18 years | |
| Alexandre Mehfar | M | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| John DeYoung | M | 61 | 33 years | |
| Kevin Kempskie | M | - | 4 years | |
| Caspar R. Tudor | M | - | 3 years | |
| John F. Cozzi | M | 62 |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Kristen Garvey | F | - | 6 years | |
| Payal Sahni Becher | F | - | 27 years | |
| Amol Chaubal | M | 48 | 3 years | |
| Cynthia Lavoie | M | - |
Anchor Therapeutics, Inc.
 Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | - |
| Trudie Resch | F | - |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 17 years |
| Jochen Knolle | M | 74 |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | - |
| Martin Eltrich | M | 51 |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 23 years |
| Brook Colangelo | M | 46 | 6 years | |
| Alan Walter Wilkinson | M | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Jianqing Bennett | F | - | 3 years | |
| Baron J. Carlson | M | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 20 years |
| Rahul Goyal | M | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 22 years |
| Daniel Rush | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Henry McKinnell | M | 81 | 8 years | |
| William Steere | M | 88 | 28 years | |
| Christopher O'Connell | M | 57 | 5 years | |
| Donald Olds | M | 64 | 2 years | |
| James Parsons | M | 58 |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | 11 years |
| Jennifer Shea | F | - | 10 years | |
| Constance J. Horner | F | 82 | - | |
| Douglas A. Berthiaume | M | 75 | 23 years | |
| Jacob M. Plotsker | M | 56 | 16 years | |
| Amy C. Bevacqua | F | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | - |
| Alan Levin | M | 62 | 20 years | |
| Jennifer Schroeder | F | - | 20 years | |
| Mathieu Boudreau | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 2 years |
| Eugene Gene Cassis | M | 67 | - | |
| Jonathan Emms | M | - | 20 years | |
| Olivier Brandicourt | M | 68 | 13 years | |
| Martin MacKay | M | 68 | 14 years | |
| Lyle Vanclief | M | - | 8 years | |
| Mairi Phillips | F | - | 12 years | |
| Joseph Akers | M | 78 |
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | - |
| Warren Whitehead | M | 71 | - | |
| Mohamed Roushdy | M | - | - | |
| Scott Dahnke | M | 59 |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | 4 years |
| Lyne Fortin | F | 64 | 3 years | |
| Brian Ford | M | 66 | 7 years | |
| Joseph M. Danis | M | - | 10 years | |
| Sherry Buck | F | 60 | 3 years | |
| Linda H. Hanauer | F | - |
AEA Investors LP
AEA Investors LP Investment ManagersFinance AEA Investors LP (AEA Investors) is a private equity firm founded in 1968 by Rockefeller, Mellon & Harriman family interests and S.G. Warburg & Co, a subsidiary of AEA Holdings LLC. The firm is headquartered in New York. | - |
| Margaret Cunningham | M | - | 10 years | |
| Albert Beraldo | M | - | 3 years | |
| M. Anthony Burns | M | 81 | 25 years | |
| JoAnn Reed | F | 68 | 15 years | |
| Gary Hendrickson | M | 67 | 4 years | |
| Mark Beaudouin | M | 69 | 16 years | |
| Charles H. Hill | M | 69 | 31 years | |
| Stanley Alkemade | M | - | 14 years | |
| John Ornell | M | 66 | 20 years | |
| Wyllie Cornwell | M | 76 | 23 years | |
| Robert N. Burt | M | 86 | 11 years | |
| Franklin Raines | M | 74 | 11 years | |
| Joshua Bekenstein | M | 65 | 23 years | |
| Laurie Glimcher | M | 72 | 22 years | |
| Bill Miller | M | 78 | 19 years | |
| Michael Brown | M | 83 | 16 years | |
| Peter Corr | M | 76 | 6 years | |
| Dana George Mead | M | 88 | 12 years | |
| Thomas W. Fry | M | 79 | 3 years | |
| John Ballbach | M | 64 | 1 years | |
| Karen Dawes | F | 72 |
Bayer Corp.
Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. | 15 years |
| Anthony Maddaluna | M | 71 | 18 years | |
| Ronald Knickerbocker | M | 58 | 5 years | |
| Randy Brenner | M | 51 | 15 years | |
| Paul E. Kirincic | M | 73 | 3 years | |
| John Borgeson | M | 62 | 21 years | |
| Pedro Lichtinger | M | 70 | 14 years | |
| Stephen Worland | M | 66 | 1 years | |
| Rajmund Ireneusz Martyniuk | M | 62 | 4 years | |
| Craig M. Audet | M | 59 | 5 years | |
| Jeroen van Beek | M | - | 8 years | |
| Peter Powchik | M | 67 | 5 years | |
| Jay Olson | M | - | 16 years | |
| Michael Tarnok | M | 69 | 18 years | |
| Mary R. Flack | M | - | 7 years | |
| Charles A. Baker | M | 91 | 19 years | |
| Bhooshitha B. de Silva | M | 49 | 11 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 86 | 86.87% |
| Canada | 13 | 13.13% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Berendt
- Personal Network
